 | |
| Clinical data | |
|---|---|
| Other names | DEPEA; NADEP;N,α-DEPEA; α,N-DEPEA;N,α-Diethylphenylethylamine;N,α-Diethylbenzeneethanamine; 2-Amino-N-ethyl-1-phenylbutane; 2-Ethylamino-1-phenylbutane; Ethyl(1-phenylbutan-2-yl)amine; EAPB; α-Et-EPEA |
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number |
|
| PubChemCID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C12H19N |
| Molar mass | 177.291 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
N,α-Diethylphenethylamine (DEPEA orNADEP), also known as2-ethylamino-1-phenylbutane (EAPB) is astimulantdrug of thephenylisobutylamine (α-ethylphenethylamine) group. It is a closechemical analog ofmethamphetamine, which has been sold as adesigner drug.[1][2][3] It was originally patented by Knoll Pharma as one of several analogs for pharmaceutical applications. In animal models these analogs showed properties of cognitive enhancement and increased pain tolerance.[4] Nevertheless, this class of compounds was never developed into a medicine.
DEPEA is a mixednorepinephrine–dopamine releasing agent (NDRA) andnorepinephrine–dopamine reuptake inhibitor (NDRI).[5] It is a full releaser of norepinephrine but a weakpartial releaser ofdopamine with amaximal efficacy of about 40% in rat brainsynaptosomes.[5] In another study however, DEPEA non-significantly released norepinephrine but did not release dopamine at all inhuman embryonic kidney 293 (HEK293)cells transfected with themonoamine transporters, whereas it continued to act as an NDRI in this system.[6] In a third study, DEPEA did not induce dopamine efflux in ratstriatalslices.[7] The drug produceshyperlocomotion, astimulant-like effect, in rodents.[5] It is approximately 10-fold lesspotent thanamphetamine in terms of this effect.[5]
DEPEA is a low-potencyagonist of the rattrace amine-associated receptor 1 (TAAR1) (EC50Tooltip half-maximal effective concentration = 3,500 nM) but was inactive as an agonist of the mouse and human TAAR1 at least up to the maximal assessed concentrations (EC50 > 4,400 nM and 30,000 nM, respectively).[6]
N,α-DEPEA has not been studied in humans, but experts such as Pieter Cohen ofHarvard Medical School expect it to be less potent than methamphetamine, but greater thanephedrine.[8]
In January 2013, the South Korean authorities reported seizing a large quantity of the pure material, predicting it would soon be found on the market.[9] Later in 2013, it was found as anadulterant in biologically significant amounts in the pre-workout supplements Craze (marketed by Driven Sports, Inc.) and Detonate (marketed by Gaspari Nutrition).[4][10] It was falsely claimed to beDendrobium extract.[8][11][12]
